𝐏𝐨𝐩𝐞 𝐅𝐫𝐚𝐧𝐜𝐢𝐬, 𝐰𝐢𝐭𝐡 𝐡𝐢𝐬 𝐩𝐞𝐨𝐩𝐥𝐞 𝐮𝐧𝐭𝐢𝐥 𝐭𝐡𝐞 𝐞𝐧𝐝. Deep and profound gratitude from the family of Università Cattolica del Sacro Cuore, Istituto G. Toniolo and Policlinico A. Gemelli The statement: secondotempo.cattolicanews.it/news-pope-fran…

Happy to have launched the 1st edition of ENDEAVOUR Lung cancer progamme in Madrid . A 3-year project that brings together highly talented medical oncologists with internationally renowned experts. Glad to see that France 🇫🇷 and Gustave Roussy are well represented !

New drugs @ASCO2025 Gustave Roussy

Too excited to sleep 🤗 Welcome in Chicago #ASCO2025 lisaderosa Gustave Roussy

BL-B01D1 (iza-bren), EGFRxHER3 ADC in driver mutation positive NSCLC outside of classical EGFR mutant NSCLC ORR in EGFR exon20ins/non classical EGFR NSCLC = 69.2% Activity also noted across other genomic alterations. #ASCO25

🔹 Gustave Roussy at #ASCO25 🔹 Dr. Antoine Hollebecque, oncologist at Gustave Roussy, presents a new combination of treatments for patients with colorectal #cancer in treatment failure at ASCO. Press release ➡ ow.ly/Ye0r50W1Z0X

Stop by the #ASCO25 Poster Session to learn about targeted treatments for BRAF-mutated NSCLC🧬 📗Available in our Targeted Therapies in NSCLC supplement, this review illuminates how new treatments are improving outcomes: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert d.planchard

Alessandro Di Federico presenting our collaborative study on 1st line BRAF/MEKi vs. #ICI for mNSCLC at #ASCO2025. ⬆️ OS with #ICI particularly in pts w/ PDL1 >1%, h/ tobacco use & TP53m. ASCO Marcelo Corassa, MD. Marcelo Negrao Dana-Farber MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

Pleasure to see Marcello Tiseo at #ASCO2025 presenting the ALNEO academic study by the GOIRC group and making the whole 🇮🇹 thoracic oncogy community proud! ASCO ALK+ International

🕰️ Chronobiological mechanisms matter in ICI efficacy. First randomised clinical trial demonstrating improvement in ORR, PFS, OS in the Early Time-of-Day (ToD) arm 🧬 great effort by Francis Lévi from ParisSaclay #ASCO2025

Impact de la supplémentation orale en Akkermansia muciniphila dans le cancer du rein (RCC) , essai ev2101 Présenté par Dr lisaderosa Gustave Roussy

I was in specialist training when we run ph1 trial with tarlatamab at Gustave Roussy (2022). #asco2025: ph3 + results ✅ EXCELLENT news for our SCLC pts. 1st aim of our careers (within and outside clinical trials): improve pts outcomes

FRONT-BRAF: 1L immunotherapy +/- chemo vs. BRAF + MEK inhibitors in mNSCLC presented by my friend and colleague Alessandro Di Federico a very kind-hearted, dedicated thoracic oncologist with a bright future ahead 🌟 🇮🇹 🇺🇸 #ASCO25 youtu.be/WgSUjS7xRJQ?si… via YouTube

Thanks #ASCO25 for the amazing opportunity to present some of the Gustave Roussy works FabriceAndre Fabrice Barlesi Christophe Massard Benjamin Besse d.planchard Barbara Pistilli Emeline COLOMBA Jordi Remon HollebecqueA JoanaMRibeiro2 Michels Judith lisaderosa and many more !

In Italy we have one of the most recognized hepatobiliary surgeon, well known for his contributions to liver surgery in the field of oncologic liver resection and minimally invasive techniques. I met him and I was very impressed from his humanity, kindness and honesty 💎

MTAP expression by immunohistochemistry: a novel biomarker in non-small cell cancer of the lung - Journal of Thoracic Oncology jto.org/article/S1556-…

Being selected as a participant in the 2025 IASLC Academy has been a unique opportunity to advance my professional path within an international community of leaders and mentees in the field of thoracic oncology! Amazed by this exciting experience 💫

Need to implement gender-informed RPM strategies towards cancer care equity. Come and visit our poster at row 25 #WCLC25 Fabrice Barlesi Gustave Roussy Ines Vaz Luis Resilience

I'm happy to share our new publication 📝 : jamanetwork.com/journals/jaman… In this cohort study, including more than 40,000 patients with #NSCLC At immunotherapy start, we found a association between survival and prescription of : Antibiotic, PPI &High dose of steroid Benjamin Besse